Palexia (Tapentadol)

Tapentadol, the active ingredient in Palexia, is an opioid analgesic presented as a strength/form for oral use. It is indicated for the management of moderate to severe acute pain in adult patients.

GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Tapentadol acts on central pain pathways to provide analgesia in several clinical settings. - Acute postoperative pain: helps control pain following surgical procedures. - Chronic musculoskeletal pain: reduces pain associated with conditions such as osteoarthritis. - Cancer‑related pain: provides relief for breakthrough pain in oncology patients.

Tapentadol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: feeling of light‑headedness or unsteadiness. - Constipation: reduced bowel movements. - Headache: mild to moderate head pain. - Somnolence: increased sleepiness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Seizures: risk of convulsive episodes. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Dependence or abuse potential: risk of developing opioid use disorder. - adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing Tapentadol, clinicians should consider several safety aspects. - Assess pain severity: ensure the drug is appropriate for the level of pain. - Review medical history: check for respiratory, hepatic or renal impairment. - Monitor for sedation: watch for excessive drowsiness or impaired cognition. - Avoid concurrent CNS depressants: limit use with alcohol or benzodiazepines. - Educate patients on proper use: stress the importance  - Store at ambient temperature: keep in original packaging  - Use  -  

A